Quoin Pharmaceuticals (Nasdaq: QNRX), a clinical-stage company targeting rare dermatological conditions, reported major clinical and regulatory momentum in its Q2 2025 update. The company is focused on advancing its lead candidate, QRX003, as a potential first approved therapy for Netherton Syndrome, a severe and underserved genetic skin disease.
Key progress includes:
- Positive six-month pediatric data showing skin improvement and no safety concerns
- FDA clearance for a second pivotal trial of QRX003
- New designation milestones including Orphan Drug status in Europe and Rare Pediatric Disease Designation in the U.S.
- Initial positive data from a pediatric Peeling Skin Syndrome study
- Ongoing NETHERTON NOW video campaign featuring patients and clinicians, increasing awareness and advocacy
“Second quarter of 2025 was one of the most impactful in Quoin’s history, marked by meaningful progress on multiple fronts,” said Dr. Michael Myers, Chief Executive Officer of Quoin Pharmaceuticals. “We continue to be encouraged by the positive and durable clinical improvements observed in our ongoing investigator-led pediatric Netherton Syndrome study. In addition, with the reporting of impressive Peeling Skin Syndrome data during the quarter, we are beginning to see the versatility of QRX003 as a potentially safe and effective treatment for a variety of rare skin diseases.”
The company remains focused on advancing QRX003 through late-stage trials and expanding its reach into other rare skin conditions with high unmet need.
The post Quoin Reports Strong Q2 as Late-Stage Netherton Syndrome Trial Progress Fuels Rare Dermatology Pipeline Expansion appeared first on PRISM MarketView.
